Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Tables)

v3.22.1
Discontinued Operations (Tables)
12 Months Ended
Dec. 31, 2021
Discontinued Operations  
Schedule of components of loss from discontinued operations as reported in our statements of operations and comprehensive loss and assets and liabilities reported as discontinued operations in our condensed balance sheets

    

Year ended

December 31, 

2020

(In thousands, except per share data)

Revenue:

 

  

Product revenue

$

376

Costs and expenses:

 

  

Cost of goods sold

 

1,332

Research and development

 

1,917

Selling, general and administrative

 

7,224

Total costs and expenses

 

10,473

Loss from discontinued operations

 

(10,097)

Other expense, net

 

738

Net loss from discontinued operations

$

10,835

Basic and diluted net loss per common share from discontinued operations

$

(2.87)

Weighted average shares used in computing basic and diluted net loss per common share

 

3,773

    

December 31, 

2021

2020

(In thousands)

Prepaid expenses and other current assets

 

12

 

181

Discontinued operations – current assets

$

12

$

181

Accounts payable

$

782

$

1,515

Accrued clinical trials expenses

 

 

80

Accrued sales allowances

 

 

61

Other accrued liabilities

 

362

 

304

Discontinued operations – current liabilities

$

1,144

$

1,960